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Abstract Overexpression of p21cip1 induces cell cycle arrest.
Although this ability has been correlated with its nuclear local-
ization, the evidence is not conclusive. The mutants that were
used to inhibit its nuclear translocation could no longer bind to
several proteins known to interact with the last 25 amino acids
of p21cip1. Here we used point mutation analysis and fusion of
the proteins to DsRed to identify which amino acids are essen-
tial for the nuclear localization of p21cip1. We conclude that
amino acids RKR140142 are essential for nuclear translocation
of p21cip1. While wild-type DsRed-p21 induces cell cycle arrest
in 95% of transfected cells, overexpression of cytoplasmatic
p21AAA140142 arrested only 20% of transfected cells. We con-
clude that cytoplasmatic p21, with no deletion in the C-terminal
region, had a much lower capacity to arrest the cell cycle.
, 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
p21cip1 (p21) belongs to the CIP/KIP family of cyclin-de-
pendent kinase (cdk) inhibitors. All the members of the family
contain conserved cyclin and cdk binding domains near the
amino-terminus. These sequences allow them to bind to al-
most all cyclin/cdk complexes and to inhibit cyclin/cdk2 com-
plexes [1^3]. Furthermore, binding of p21 to cyclin D/cdk4
provides the complex with a nuclear localization signal
(NLS) [4] and blocks exposure of nuclear export sequences
of cyclin D [5]. p21 has additional characteristics that assign
it a unique role in cell cycle regulation. It is an important
element in cell cycle arrest induced by DNA damage [6], dif-
ferentiation and senescence [7]. It has also been implicated in
inhibition of DNA re-replication [8^10] and in apoptosis pro-
tection [11]. The C-terminal half of p21 is di¡erent from the
other CIP/KIP family members, and it binds to proliferating
cell nuclear antigen (PCNA) and inhibits DNA replication in
vitro [12,13]. Recently, another cyclin A/E and a cdk4 binding
domain were found in the C-terminus region of p21 [14,15].
Furthermore, other proteins such as calmodulin [16], SET
[17], GADD45 [18], c-myc [19], c/EBPK [20] and CARB [21]
bind to the C-terminus of p21. Almost all these binding do-
mains overlap with each other and with the PCNA binding
domain [22].
Separate expression of the N- and C-terminal region of p21
showed that each domain inhibits the cell cycle independently
[2]. The C-terminal half of p21 is also responsible for its
nuclear localization and putative NLSs are present in this
region. Nuclear translocation of p21 is positively modulated
by calmodulin and negatively by AKT-dependent phosphory-
lation [16,23]. Although cell growth-inhibiting activity of p21
is strongly correlated with its nuclear localization [13,24], the
evidence is not conclusive since all attempts to obtain cyto-
plasmatic p21 used p21-deleted mutants (p211140). These mu-
tants eliminated not only the putative NLSs within the C-
terminal domain but also the binding domain to proteins
that interact with the last amino acids of p21. Consequently,
lack of inhibition could be due to the inability of p21 to bind
some of these proteins. Here we identi¢ed which amino acids
are essential for the nuclear translocation of p21. We then
analyzed the cell growth inhibitory activity of p21 containing
NLS mutations which blocked the nuclear entry.
2. Materials and methods
2.1. Plasmid construction and mutagenesis
Prediction of NLS sequences was performed using PSORTII pro-
gram (http://psort.nibb.ac.jp). All recombinant p21 cDNA constructs
were derived from the human cDNA (gift from Dr. Massague¤, Me-
morial Sloan-Kettering Cancer Center, New York). Polymerase chain
reaction (PCR) ampli¢cation was performed using a 32-mer initial
forward oligonucleotide (5P-gTgggAATTCgCATATgTCAgAACC-
ggCTggg-3P) and a 33-mer terminal reverse oligonucleotide (5P-AC-
gAggATCCAAgCTTTAgggCTTCCTCTTggA-3P) to amplify the full-
length cDNA and a 30-mer middle forward oligonucleotide (5P-
ggCCggAATTCgCATATgggAggCAggCgg-3P) and the same terminal
reverse oligonucleotide to amplify the C-terminal half of the cDNA.
Digestions with NdeI and HindIII allowed cloning into a modi¢ed
pGEX-KG and digestions with EcoRI and BamHI allowed cloning
into pDsRed and pEGFP-C1 (GFP, green £uorescent protein) (Clon-
tech). The p21AAA161163 mutant was obtained by single PCR am-
pli¢cation using a reverse 48-mer oligonucleotide (5P-ACgAggATC-
CAAgCTTTAgggCgCCgCCgCggAgAAgATCAgCCggCg-3P) car-
rying the mutation (shown in bold). The p21AAA140142-AAA161163
and the p21AAA140142 were obtained by two-stage PCR using mega-
primers. The ¢rst PCR reaction was performed using a 45-mer middle
forward oligonucleotide (5P-ggACCTggAgACTCTCAgggTgCggCC-
gCgCggCAgACCAgCATg-3P) carrying the corresponding mutations
(shown in bold) and a reverse terminal oligonucleotide wild type or
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carrying the AAA161163 mutation as shown above. The second PCR
product was performed using the 32-mer initial forward oligonucleo-
tide (for the full-length construct) or the 30-mer middle forward oli-
gonucleotide (for the carboxy-terminal construct) and the ¢rst PCR
product (megaprimer of 114 bp) as reverse mutated primer.
2.2. Cell culture and transfections
NIH3T3 and COS-7 cells were grown in Dulbecco’s minimum es-
sential medium (DMEM) supplemented with 10% donor calf serum
(DCS) or 5% fetal calf serum (FCS), respectively. Transient expression
of the di¡erent p21 mutants was achieved by transfecting the cells
using E¡ecten reagent (Qiagen) following the manufacturer’s instruc-
tions.
2.3. Immunocytochemistry and confocal analysis
For intracellular localization analysis of DsRed and GFP fusion
proteins, cells were grown on coverslips and ¢xed in 3% paraformal-
dehyde/phosphate-bu¡ered saline (PBS) (140 mM NaCl, 5 mM
Na2HPO4, 1.5 mM KH2PO4, pH 7.2) for 20 min at room temper-
ature. Fluorescence was analyzed by confocal microscopy. For BrdU
immunocytochemistry cells were ¢rst incubated for the indicated time
with BrdU (10 WM) and then ¢xed as above, permeabilized with 0.2%
Triton X-100 in PBS for 10 min at room temperature, blocked for 20
min with 10% FCS in PBS and then incubated for 90 min with DNase
(Boehringer, cat. #776785, 1:1 dilution in PBS) and then for 1 h at
37‡C in a humidi¢ed atmosphere with monoclonal anti-BrdU anti-
body (Boehringer, cat. #1179376, 6 Wg/ml). Fluorescein-conjugated
secondary antibodies were used.
2.4. Protein expression and puri¢cation, pull-downs and cdk2 assay
pGEX-KG vectors containing either the di¡erent mutations of p21,
cdk2, SET or cyclin A and the PET vector containing the PCNA-His
tag were transformed into Escherichia coli BL21(DE3) strain carrying
the pLysS plasmid. The expression and puri¢cation were performed
using glutathione-a⁄nity [17] or Ni-a⁄nity chromatography accord-
ing to the manufacturer (Novagen). GST was cut o¡ from SET by
digestion with thrombin protease according to the manufacturer (Sig-
ma). Human recombinant CaM was also expressed in E. coli and
puri¢ed as previously described [25]. Puri¢ed proteins were covalently
bound to BrCN-activated Sepharose 4B, as indicated by manufac-
turers. Pull-downs were performed as follows: 1 Wg of puri¢ed protein
was incubated for 1 h at 4‡C with 20 Wl of either CaM-Sepharose (1:1
v/v), SET-Sepharose (1:1 v/v) or PCNA-Sepharose (1:1 v/v) in 50 mM
Tris^HCl pH 7.4, 150 mM NaCl, 1% Triton X-100 (the bu¡er also
contained 0.1 mM CaCl2 for CaM-Sepharose pull-downs). After cen-
trifugation, unbound proteins were collected and bound proteins
washed three times in the same bu¡er and eluted directly with sodium
dodecyl sulfate (SDS)^polyacrylamide gel electrophoresis Laemmli
loading bu¡er, electrophoresed and analyzed by Silver staining.
Cdk2 activity was determined as previously described [17] using puri-
¢ed proteins. Where indicated puri¢ed wild-type or mutated 400 nM
p21-GST (equimolar to cdk2) was added.
3. Results
3.1. Determination of p21 NLS
PSORTII analysis of p21cip1 sequence gave three putative
‘classical type’ NLSs and three overlapping bipartite NLSs
within the last 25 amino acids (Fig. 1). In order to identify
which of the sequences was responsible for the nuclear
localization of p21, site directed mutagenesis was performed
to change the crucial amino acids. The following mutations
were performed: p21AAA140142-AAA161163, p21AAA140142,
p21AAA161163 (Fig. 1C). Wild-type p21 (p21WT) and the
various mutations were fused to GFP or to DsRed and trans-
fected to NIH3T3 (Fig. 2) and to COS (data not shown) cells
in order to analyze subcellular localization. GFP-p21WT and
DsRed-p21WT were all nuclear. Simultaneous mutation
of RKR140142 and KRK161163 regions, p21AAA140142-
AAA161163 mutant, induced an increase in cytoplasmatic pro-
tein in 95% of the cells when fused to GFP, and gave a
completely cytoplasmatic protein in 95% of the cells when
fused to DsRed. p21AAA161163 mutant fused to GFP or to
DsRed was still nuclear while p21AAA140142 was more abun-
dant in the cytoplasm when fused to GFP and totally cyto-
plasmatic in 98% of the cells when fused to DsRed. The di¡er-
ences between the subcellular localization of the DsRed- and
GFP-fused mutants could re£ect the fact that DsRed proteins
oligomerize and in consequence the molecular weight of
DsRed-p21 proteins is far from the limit for the passive dif-
fusion through the nuclear pore, while p21-GFP might par-
tially di¡use to the nucleus. These results showed that amino
acids RKR140142 are essential for the nuclear localization of
p21 while the AAA161163 are not. Thus, from now we will
refer to p21AAA140142 as p21NLS3 mutant.
3.2. p21NLS3 preserves the capacity to inhibit cdk2 and to
bind to PCNA, SET and CaM in vitro
p21WT and p21NLS3 were puri¢ed as GST-fused proteins
and incubated with cyclin A^cdk2 complexes. Cdk2 kinase
activity was then determined by using histone H1 as substrate.
As shown in Fig. 3A, the inhibitory activity of p21NLS3 on
cdk2/cyclin A was similar to the one of p21WT. Pull-downs
were performed using PCNA-His, SET and CaM bound to
Sepharose to analyze the capacity of p21NLS3 mutant to
bind to these proteins. As shown in Fig. 3B, mutation of
amino acids RKR140142 to AAA140142 did not alter binding
of p21 to either PCNA, SET or CaM.
3.3. E¡ect of cytoplasmatic p21 on cell proliferation
Transfections were performed with WT or NLS mutated
p21, in NIH3T3 cells, and the e¡ect on cell cycle was deter-
mined by 8 h BrdU incorporation into the cells followed by
immunocytochemistry and quanti¢cation of the percentage of
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“Classic type” NLS at 161 RKRRQTSMTDFYHSKRRLIFSKRKP
p21CIP1 binding proteins and interaction domains
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p21AAA140-142-AAA161-163 AAARQTSMTDFYHSKRRLIFSAAAP
p21AAA140-142 AAARQTSMTDFYHSKRRLIFSKRKP
p21AAA161-163 RKRRQTSMTDFYHSKRRLIFSAAAP
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Fig. 1. p21cip1 domains and mutants used. A: p21cip1 binding pro-
teins and interacting domains. B: PSORTII predicted NLS sequen-
ces in the carboxy-terminal region of p21cip1. Putative essential ami-
no acids are shown in bold. C: p21cip1 mutants were generated as
indicated in experimental procedures. Mutated amino acids are
shown in bold. The rest of the protein sequence (not shown) was
not modi¢ed.
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BrdU positive cells among transfected and non-transfected
cells (Fig. 4). As previously described nuclear expression of
p21 strongly inhibited cell proliferation. The proliferative in-
hibitory activity of p21 was highly reduced when the protein
was cytoplasmatic. The remaining inhibitory activity could be
due to a retention of cdk4/cyclin D1 in the cytoplasm as a
consequence of its binding to the cdk and cyclin binding do-
mains present in the amino-terminal half of p21NLS3. In fact,
retention of cyclin D1 in the cytoplasm was observed in
p21NLS3, compared with p21WT, transfected cells (data
not shown). To rule out the possibility that binding of p21
C-terminal domain to cytoplasmatic proteins has an inhibi-
tory e¡ect on the cell cycle, NIH3T3 cells were transfected
with C-terminal (amino acids 91^164) wild-type p21
(CTp21WT) or NLS mutated p21 (CTp21NLS3) and cell
Fig. 2. Intracellular localization of the p21cip1 mutants fused to
GFP or to DsRed. NIH3T3 cells were transfected with p21WT,
p21AAA140142-AAA161163, p21AAA140142, p21AAA161163 fused
to either GFP or DsRed. Localization of expressed fusion proteins
was analyzed by confocal microscopy. Examples of typical localiza-
tions of the various proteins are shown.
Fig. 3. Ability of p21NLS3 mutant to inhibit cdk2/cyclin A and to
bind PCNA, SET and CaM. A: Inhibition of cdk2/cyclin A by
GST-p21WT and GST-p21AAA140142. Cdk2/cyclin A activity was
analyzed in the absence of p21 (3), or in the presence of either
GST-p21 (p21WT) or GST-p21AAA140142 (p21NLS3). B: Binding
of GST-p21WT and GST-p21AAA140142 to CaM, SET and PCNA.
Bound proteins and input (20%) were electrophoresed and silver
stained.
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Fig. 4. E¡ect of di¡erent p21cip1 mutants on cell proliferation.
NIH3T3 cells were transfected with either p21WT, p21AAA140142,
CTp21WT or CTp21AAA140142, all fused to DsRed. Cells were
trypsinized 24 h after transfection and grown on coverslips for a
further 24 h at 30% con£uence. During the last 8 h the cells were
incubated in the presence of BrdU. They were then ¢xed and BrdU
incorporation was analyzed by immunocytochemistry using an
FITC-conjugated secondary antibody. The di¡erent DsRed fusion
proteins are shown in the red channel and the BrdU incorporation
in the green. A: Representative microscope image after transfection
with the di¡erent DsRed-p21 constructs. Arrows show location of
DsRed-p21 transfected cells. B: Percentage of BrdU positive cells
for each p21 construct transfected cells or for non-transfected cells
(3). Only cells with cytoplasmatic localization of p21 were counted
for CTp21NLS3. The experiment was performed in triplicate, and
for each experiment at least 100 transfected cell were counted.
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proliferation analyzed. While overexpression of nuclear C-ter-
minal p21 inhibited cell cycle with the same e⁄ciency as full-
length p21, C-terminal cytoplasmatic p21 did not inhibit the
cell cycle (Fig. 4). Interestingly, in 50% of the cells C-terminal
NLS mutated p21 entered the nucleus and in those cells the
inhibitory capacity was re-established. All these experiments
were also performed with COS cells with similar results (data
not shown).
4. Discussion
Here we identi¢ed the amino acids of p21 that are essential
for its nuclear translocation and examined the consequences
of their mutation. While the RKR140142 sequence was essen-
tial for nuclear localization of p21, the KRK161163 was not.
Together with the PSORTII analysis, this indicates that either
the bipartite NLS located in the sequence RKRRqtsmtdf-
yhsKRR140156 or the classic pattern of four amino acids,
RKRR140143, is responsible for the nuclear translocation of
p21.
The use of DsRed-fused mutants led us to this conclusion
while the GFP-fused proteins gave confusing results. When we
mutated the RKR141142 amino acids to AAA140142 and fused
the p21 cDNA to GFP, the cytoplasmatic expression of GFP-
fused protein increased signi¢cantly but the remaining nuclear
localization suggested the presence of another NLS. In con-
trast, when the same mutated cDNA was fused to DsRed
proteins, the nuclei were completely devoid of DsRed protein.
The di¡erent results obtained with GFP- or DsRed-fused p21
mutants could be due to the fact that DsRed proteins oligo-
merize [26] while GFP do not. Thus, the molecular weight of
GFP-p21 fusion proteins is close to the limit for nuclear dif-
fusion through the nuclear pores, while DsRed-p21 proteins
are much bigger. Although it could be argued that p21 has a
low molecular weight and in consequence the GFP-p21 fusion
is closer to the situation in vivo, the amount of free p21 in the
cell may be small, and most of the p21 is found in high
molecular complexes such as p21/cdk/cyclin, which will need
an NLS for their nuclear translocation.
Although di¡erent data support the hypothesis that nuclear
p21 inhibits proliferation while cytoplasmatic does not, stud-
ies were based on p21 deletions that compromised the last 25
amino acids, and in consequence the capacity to bind to var-
ious proteins [13,24]. The fact that the peptide spanning ami-
no acids 139^164 exhibits cdk inhibitory activity when intro-
duced to human cells [14,27] emphasizes the importance of
this deleted domain in cell cycle regulation. Furthermore,
those mutants were usually expressed fused to GFP or small
tags, and consequently the proteins were still partially nuclear.
The determination of the NLS of p21 and the construction of
the DsRed-p21NLS3 fused mutant allowed us to analyze the
e¡ect of cytoplasmatic versus nuclear p21 on cell prolifera-
tion.
In agreement with previous results we found that overex-
pression of nuclear p21WT strongly inhibits cell proliferation
[2,13,24,28]. In contrast, cytoplasmatic p21-NLS3 is less able
to inhibit cell proliferation (only 20% inhibition with respect
to nuclear p21WT). Because p21NLS3 mutant inhibits cdk2/
cyclin A activity in vitro, we conclude that p21 does not bind
or inhibit cdk2/cyclin A when this complex is in the cyto-
plasm. The remaining cell proliferation inhibitory activity of
p21NLS3 mutant may be due to retention of cdk4/cyclin D1
complex in the cytoplasm as already described [28]. To rule
out the possibility that binding of a cytoplasmatic protein to
the C-terminal region of p21 partially inhibited cell prolifer-
ation, wild-type C-terminal p21 (CTp21WT) or C-terminal
p21 with mutated NLS (CTp21NLS3) were fused to DsRed.
Interestingly, CTp21WT was completely nuclear and inhibits
cell proliferation as strongly as the full-length protein, indicat-
ing an important role in cell cycle of the proteins that bind to
the carboxy-terminus of p21. In contrast, CTp21NLS3 was
cytoplasmatic in 50% of the cells, in which cases it did not
inhibit cell proliferation, con¢rming that the remaining inhib-
itory activity of p21NLS3 was due to the N-terminal region.
Mutations performed to obtain the NLS3 mutant did not
a¡ect the amino acids essential for cdk4 [15] or cycE/A [14]
binding to the C-terminal region. Furthermore we have shown
that p21NLS3 is able to interact with PCNA, CaM and SET.
Thus, we also conclude that interaction with any of those
proteins must take place in the nucleus if proliferation is to
be inhibited. Con¢rming that, cell cycle was arrested in cells
with CTp21NLS3 in the nucleus. We do not know why a
lower proportion of CTp21NLS3 than full-length p21NLS3
was exclusively cytoplasmatic, but it may indicate the presence
of a cytoplasmatic retention sequence or a nuclear export
signal in the N-terminal region.
We have identi¢ed the amino acids responsible for the nu-
clear translocation of p21 and shown that cytoplasmatic p21,
although able to bind to PCNA, SET, CaM, cdk4 and cyclin
A/E, has a reduced inhibitory e¡ect on the cell cycle. Consid-
ering the di¡erent roles of nuclear and cytoplasmatic p21, it is
not surprising that its entrance, and probably the exit, into
and out from the cell nucleus are highly regulated [16,23].
Further analysis of these mechanisms promises to be relevant
in cell proliferation, apoptosis and oncogenesis areas.
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